Eumentis Therapeutics Inc
EuMentis Therapeutics Inc. is a privately held, clinical stage biotech company focused on the development of novel therapeutics to treat neuropsychiatric conditions with high unmet need. The Company’s lead product, EM-221, is a best-in-class, oral, PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum. EuMentis has completed three successful Phase 1 studies and plans to initiate a Phase 2b study of EM-221 for the treatment of schizophrenia in 1H 2026. It is currently raising $50 mm to finance the schizophrenia program and or $25 mm to fund the Parkinson's LID Ph 2 trial. The Company also has a novel, patented (composition of matter), next generation NMDAR antagonist in pre-clinical development that is being spun out.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
7
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Eumentis Therapeutics Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
- MT
Mark Tepper
President & CEO · Other
EmailPhone - JE
Jo Emmett
Senior Vice President, Eumentis Therapeutics · Other
EmailPhone
Showing 2 of 2 verified contacts
Top roles at Eumentis Therapeutics Inc
2 distinct titles indexed · top 2 shown.
- 1president & ceo
- 1senior vice president, eumentis therapeutics
Sign up to unlock all 2 contacts at Eumentis Therapeutics Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Eumentis Therapeutics Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.